Candela推出用于治疗血管和皮肤病的革命性 Vbeam Pro®激光平台-动脉网

Candela Launches Revolutionary Vbeam Pro® Laser Platform for the Treatment of Vascular and Dermatologic Conditions

CISION 等信源发布 2025-04-24 21:23



可切换为仅中文







Vbeam Pro will be unveiled at the 2025 Annual Meeting of American Society for Laser Medicine and Surgery (ASLMS)

Vbeam Pro 将在2025年美国激光医学与外科学会（ASLMS）年会上亮相。

MARLBOROUGH, Mass.

马萨诸塞州马尔伯勒

，

April 24, 2025

2025年4月24日

/PRNewswire/ -- Candela Corporation, a global leader in energy-based medical aesthetics, proudly announced the launch of the

/PRNewswire/ -- 全球领先的能量医疗美容公司Candela Corporation自豪地宣布推出

Vbeam Pro

platform at the 2025 Annual Meeting of the American Society for Laser Medicine and Surgery (ASLMS), held in

平台将于2025年美国激光医学与外科学会（ASLMS）年会上推出，

Orlando, FL.

奥兰多，佛罗里达州。

Representing the most significant advancement in Candela's four-decades of clinical leadership in pulsed dye laser (PDL) technology, the Vbeam Pro device sets a new market standard for the treatment of vascular and dermatologic conditions.

代表了Candela在脉冲染料激光（PDL）技术领域四十年临床领导地位的最重要进步，Vbeam Pro设备为血管和皮肤病治疗树立了新的市场标准。

继续阅读

Vbeam Pro Logo

Vbeam Pro标志

Vbeam Pro Device

Vbeam Pro 设备

The

Vbeam Pro

device is the only vascular laser

设备是唯一的血管激光器

FDA-cleared for use in pediatric patients

获FDA批准用于儿科患者

and combines an advanced

并结合了先进的

595 nm pulsed dye laser

595纳米脉冲染料激光器

with a

带着一个

1064 nm Nd:YAG wavelength

1064 nm Nd:YAG 波长

to offer unmatched precision, accuracy, and treatment versatility. The platform is designed to effectively treat a broad spectrum of skin conditions, including rosacea, port-wine stains, acne, leg veins, spider veins, scars, benign pigmented lesions, wrinkles, warts, stretch marks, and photoaging.

提供无与伦比的精确性、准确性和治疗多功能性。该平台旨在有效治疗广泛的皮肤状况，包括玫瑰痤疮、葡萄酒色斑、痤疮、腿部静脉、蜘蛛静脉、疤痕、良性色素性病变、皱纹、疣、妊娠纹和光老化。

'The Vbeam Pro system is a transformative evolution in pulsed dye laser technology,' says

“Vbeam Pro系统是脉冲染料激光技术的革命性演变，”

Dr.

博士

Roy Geronemus

罗伊·杰罗内穆斯

, Clinical Professor in the Department of Dermatology at NYU Grossman School of Medicine and Medical Director of the Vascular Birthmarks Foundation. 'The clinical results are remarkably consistent, and patients are experiencing enhanced outcomes compared to earlier-generation systems,' he adds.

，纽约大学格罗斯曼医学院皮肤科临床教授，血管胎记基金会医学主任。他补充说：“临床结果非常一致，患者相比早期系统获得了更好的效果。”

With its dual wavelengths and

凭借其双波长和

30% tighter energy delivery control

能量输送控制精确度提高30%

, the Vbeam Pro laser offers a new level of efficacy and efficiency for clinicians treating patients across

，Vbeam Pro激光为临床医生治疗患者提供了更高水平的功效和效率。

all Fitzpatrick skin types (I–VI)

所有Fitzpatrick皮肤类型（I–VI）

. The platform also features optimized dye life and an enhanced user interface, delivering a superior treatment experience for both practitioners and patients.

该平台还具有优化的染料寿命和增强的用户界面，为从业者和患者提供更优的治疗体验。

Backed by rigorous clinical research, the

以严格的临床研究为后盾，

Vbeam Pro laser has demonstrated:

Vbeam Pro激光展示了：

20% improved clearance

清除率提高20%

of treated lesions¹

治疗过的病灶¹

50% faster treatment times²

治疗时间快50%²

20% reduction in reported patient discomfort³

患者报告的不适感减少20%³

'Reinforcing Candela's commitment to scientific rigor, the Vbeam Pro system underwent extensive clinical evaluation at leading dermatology practices across

“为了加强Candela对科学严谨性的承诺，Vbeam Pro系统在领先的皮肤科诊所进行了广泛的临床评估。

the United States

美国

,' says

，' 说

Konika Patel Schallen

康妮卡·帕特尔·沙伦

, MD

，医学博士

, Senior Vice President of Clinical Operations and Medical Director at Candela. 'We put the platform through stringent testing, using it in busy clinical environments on a wide variety of skin types and conditions. We are excited about the feedback from our dermatology users on enhancing patient outcomes and treatment efficiency.' she concludes..

，Candela临床运营高级副总裁兼医学总监。“我们对该平台进行了严格的测试，在繁忙的临床环境中使用，针对各种各样的皮肤类型和状况。我们对皮肤科用户在提升患者疗效和治疗效率方面的反馈感到非常兴奋。”她总结道。

'Building on Candela's longstanding clinical leadership, the introduction of the Vbeam Pro system represents a major leap forward in the treatment of vascular and other skin conditions,' said

“基于Candela长期以来的临床领导地位，Vbeam Pro系统的推出代表了在治疗血管性和其他皮肤问题方面的重大飞跃，”

Geoffrey Crouse

杰弗里·克鲁斯

, Chief Executive Officer of Candela. 'This milestone launch reflects our unwavering commitment to continuous innovation, rooted in proven science, consistent clinical outcomes, and trusted partnerships with both healthcare providers and patients.'

Candela首席执行官表示：“这一里程碑式的上市反映了我们对持续创新的坚定承诺，这些创新基于经过验证的科学、始终如一的临床结果，以及与医疗保健提供者和患者值得信赖的合作伙伴关系。”

Attendees of

与会者

ASLMS 2025

are invited to experience the Vbeam Pro device by visiting

受邀通过访问体验Vbeam Pro设备

Candela at Booth #321

坎德拉在321号展位

。

For more information, please visit:

欲了解更多信息，请访问：

candelamedical.com